21-30 of 560 results
High Court finds no authorisation of copyright infringement in Real Estate Tool Box Pty Ltd v Campaigntrack Pty Ltd
The High Court has delivered judgment in the matter of Real Estate Tool Box Pty Ltd v Campaigntrack Pty Ltd [2023] HCA 38, overturning the Full Federal Court's decision to find that Real Estate Tool Box and the other appellants did not authorise copyright infringement. ...
InIP: What's happening in intellectual property - December 2023
Your regular wrap-up of some of the world's leading and intriguing IP stories. ...
InIP: What's happening in intellectual property - November 2023
Your regular wrap-up of some of the world's leading and intriguing IP stories. ...
Mastering IP opportunities and risks in the age of AI
Covered in this webinar: Unravelling the IP opportunities and challenges presented by AI: best practices for safeguarding your IP assets and protecting against IP infringement risks; Crossing borders: analysing the Getty Images v Stability AI case in the UK, including applying an Australian lens; and Developments in AI regulations: how the EU AI Act may affect Australian businesses. ...
IP Australia releases new guidance on classifying emerging technology trade marks
IP Australia recently released new guidance on how to classify trade mark goods and services that relate to the emerging technologies of virtual goods, the metaverse, non-fungible tokens (NFTs) and blockchains. We outline how the guidance may be relevant to your business and also provide some practical suggestions for dealing with applications and registrations affected by it. ...
In Touch: Delta's bid rigging on full display; and other developments
The latest in competition and consumer law. ...
InIP: What's happening in intellectual property - August 2023
Your regular wrap-up of some of the world's leading and intriguing IP stories. ...
Australian Government takes its $325 million damages claim to the High Court in Commonwealth v Sanofi
The Full Court has confirmed that the Australian Government is not entitled to any damages from Sanofi and Bristol-Myers Squibb. In this Insight, we examine the appeal decision and consider its implications for patent infringement proceedings relating to pharmaceutical products. ...